Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections

Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections
复制标题

亚胺培南治疗铜绿假单胞菌和其他严重细菌感染

DOI:
--
复制
发表时间:
1984
影响因子:
4.9
通讯作者:
R. Busuttil
R. Busuttil
中科院分区:
医学2区
文献类型:
--
作者:
D. Winston;M. McGrattan;R. Busuttil

文献摘要

参考文献

被引文献

相似文献

亚胺培南是第一种新型β-内酰胺类抗菌药物,对最常见的分离细菌病原体具有显著和极其有效的体外活性,包括金黄色葡萄球菌、肠球菌、肠杆菌科成员、铜绿假单胞菌、脆弱拟杆菌和流感嗜血杆菌。对亚胺培南治疗35例38种不同感染的临床疗效和毒副反应进行了评价。89%的感染(38例中的34例)的总体临床反应良好(感染治愈或改善)。在17例铜绿假单胞菌感染中,15例治愈或好转。然而,铜绿假单胞菌分离耐亚胺培南出现在6例感染的治疗过程中,两例铜绿假单胞菌败血症后来复发亚胺培南治疗后。胃肠道毒性(恶心伴或不伴呕吐)发生在17%的患者中(35例中有6例),但通过减慢静脉输注速率或降低亚胺培南剂量而得到改善。除某些严重的铜绿假单胞菌感染外,亚胺培南对敏感微生物引起的感染是有效且相对安全的治疗方法。
Imipenem is the first of a new class of beta-lactam antimicrobial agents with remarkable and extremely potent in vitro activity against most commonly isolated bacterial pathogens, including Staphylococcus aureus, enterococcus, members of the family Enterobacteriaceae, Pseudomonas aeruginosa, Bacteroides fragilis, and Hemophilus influenzae. The clinical efficacy and toxicity of imipenem were evaluated in 35 patients with 38 different infections. The overall clinical response was favorable (infections cured or improved) in 89% of the infections (34 of 38). Of the 17 infections with P. aeruginosa, 15 were cured or improved. However, P. aeruginosa isolates resistant to imipenem emerged during the therapy of six infections, and two cases of P. aeruginosa septicemia later relapsed after imipenem therapy. Gastrointestinal toxicity (nausea with or without emesis) occurred in 17% of the patients (6 of 35) but was ameliorated by slowing the rate of intravenous infusion or lowering the dose of imipenem. Except for certain severe P. aeruginosa infections, imipenem is effective and relatively safe therapy for infections caused by susceptible organisms.
莫沙内酰胺加哌拉西林与莫沙内酰胺加阿米卡星治疗发热性粒细胞减少症患者的比较。
DOI: 10.1016/0002-9343(84)90100-1
发表时间: 1984
期刊: The American journal of medicine
影响因子: --
作者:
Winston,DJ;Barnes,RC;Ho,WG;Young,LS;Champlin,RE;Gale,RP
通讯作者: Gale,RP
接受免疫抑制治疗的患者出现凝固酶阴性葡萄球菌菌血症。
DOI: --
发表时间: 1983
影响因子: --
作者:
Winston,DJ;Dudnick,DV;Chapin,M;Ho,WG;Gale,RP;Martin,WJ
通讯作者: Martin,WJ